Viatris reported $1.15B in Ordinary Share Capital for its fiscal quarter ending in September of 2026.





Ordinary Share Capital Change Date
Celltrion KRW 228.57M 1.08M Jun/2026
Cspc Pharmaceutical CNY 11.52B 3.7M Dec/2025
Deva Holding AS TRY 200.02M 0 Sep/2023
Dianthus Therapeutics USD 54.8M 215.59K Jun/2026
Divis Laboratories Ltd INR 265.47M 0 Sep/2026
Kangmei Pharma CNY 13.83B 0 Jun/2026
Knight Therapeutics CAD 99.68M 24.66K Sep/2025
Laboratorios Farma EUR 51.82M 1.55M Dec/2023
Malin Corporation EUR 200K 0 Dec/2024
Medical Developments International AUD 112.66M 2.35M Dec/2025
Neuren Pharmaceuticals AUD 126.64M 38.63M Dec/2025
Organigram Holdings CAD 140.98M 4.51M Jun/2026
Ovoca Bio EUR 29.49M 0 Dec/2025
Pharma Mar EUR 17.34M 0 Sep/2026
Qiagen NV USD 206.5M 245K Jun/2026
Sartorius EUR 69.05M 0 Sep/2026
Sino Biopharmaceutical CNY 17.89B 30.5M Jun/2025
Tilray USD 116.52M 5.01M Sep/2025
Viatris USD 1.15B 8.79M Sep/2026
Zealand Pharma A/S 70.66M 53K Mar/2026
Zz Pientze Pharmaceu CNY 603.32M 0 Sep/2026